Found: 5
Select item for more details and to access through your institution.
Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 333, doi. 10.1007/s40262-023-01342-3
- By:
- Publication type:
- Article
Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization.
- Published in:
- Pulmonary Therapy, 2021, v. 7, n. 2, p. 455, doi. 10.1007/s41030-021-00158-5
- By:
- Publication type:
- Article
Measurement properties of the one-minute sit-to-stand test in children and adolescents with cystic fibrosis: A multicenter randomized cross-over trial.
- Published in:
- PLoS ONE, 2021, v. 16, n. 2, p. 1, doi. 10.1371/journal.pone.0246781
- By:
- Publication type:
- Article
High Rate of Macrolide Resistance in Staphylococcus aureus Strains from Patients with Cystic Fibrosis Reveals High Proportions of Hypermutable Strains.
- Published in:
- Journal of Infectious Diseases, 2003, v. 187, n. 11, p. 1709, doi. 10.1086/374937
- By:
- Publication type:
- Article